Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Opportunities to Optimize Cancer Policies Panel Discussion

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement

Nov

07

Today In Oncology

Long-Term Survivors of Hodgkin Lymphoma May Face Elevated Health Risks, Study Finds

OptiTROP-Lung06 A Potential Alternative to Chemotherapy in Advanced PD-L1–Negative NSCLC?

Ponatinib/Blinatumomab Improves Event-Free Survival in Ph-Positive ALL

American Lung Association and Prevent Cancer Foundation Host Virtual QIW Workshop: Advancing Routine Clinical Use of Health Information From Chest CT Screening for Public Health

Izalontamab Brengitecan Improves Progression-Free Survival in EGFR-Mutated Advanced Nonsquamous NSCLC

Advertisement

© 2026 HSP News Service, L.L.C.